Publikationer

Kalenderår 2022

Willén L, Berglund A, Bergström S, Isaksson J, Bergqvist M, Wagenius G, Lambe M. Patterns of care and outcomes in immigrants with non-small cell lung cancer. A population-based study (Sweden). PLoS One. 2022 Dec 15;17(12):e0278706. doi: 10.1371/journal.pone.0278706. PMID: 36520832; PMCID: PMC9754210.

Enlund M, Berglund A, Enlund A, Bergkvist L. Volatile versus Propofol General Anesthesia and Long-term Survival after Breast Cancer Surgery: A National Registry Retrospective Cohort Study. Anesthesiology. 2022 Sep 1;137(3):315-326. doi: 10.1097/ALN.0000000000004309. PMID: 35759394.

Berglund A, Berkö S, Lampa E, Sejersen T. Survival in patients diagnosed with SMA at less than 24 months of age in a population-based setting before, during and after introduction of nusinersen therapy. Experience from Sweden. Eur J Paediatr Neurol. 2022 Sep;40:57-60. doi: 10.1016/j.ejpn.2022.07.005. Epub 2022 Jul 31. PMID: 35973318.

Isaksson J, Wennström L, Branden E, Koyi H, Berglund A, Micke P, Mattsson JSM, Willén L, Botling J. Highly elevated systemic inflammation is a strong independent predictor of early mortality in advanced non-small cell lung cancer. Cancer Treat Res Commun. 2022;31:100556. doi: 10.1016/j.ctarc.2022.100556. Epub 2022 Apr 7. PMID: 35429913.

Willén L, Berglund A, Bergström S, Isaksson J, Bergqvist M, Wagenius G, Lambe M. Are older patients with non-small cell lung cancer receiving optimal care? A population-based study. Acta Oncol. 2022 Mar;61(3):309-317. doi: 10.1080/0284186X.2021.2000637. Epub 2021 Nov 14. PMID: 34779354.

Kalenderår 2021

Yu H, Brustugun OT, Ekman S, Botling J, La Fleur L, Micke P, Solberg S, Berglund A, Rivard C, Hirsch FR. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer. Clin Lung Cancer. 2021 Jul;22(4):e555-e562. doi: 10.1016/j.cllc.2020.09.018. Epub 2020 Oct 15. PMID: 33214079.

Embring A, Onjukka E, Mercke C, Lax I, Berglund A, Bornedal S, Wennberg B, Dalqvist E, Friesland S. Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects. Cancers (Basel). 2021 Jun 25;13(13):3173. doi: 10.3390/cancers13133173. PMID: 34202135; PMCID: PMC8269009